News headlines about AcelRx Pharmaceuticals (NASDAQ:ACRX) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 47.5268452792708 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) opened at $1.95 on Friday. The company has a current ratio of 4.78, a quick ratio of 4.71 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $5.75.

ACRX has been the subject of a number of research analyst reports. Royal Bank of Canada set a $6.00 target price on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. ValuEngine cut AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 15th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 3rd. Piper Jaffray Companies reissued a “hold” rating and set a $2.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, October 13th. Finally, Roth Capital set a $8.00 target price on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $6.83.

In related news, Director Mark G. Edwards purchased 30,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the transaction, the director now directly owns 150,000 shares of the company’s stock, valued at $285,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the sale, the insider now owns 16,379 shares of the company’s stock, valued at $86,644.91. The disclosure for this sale can be found here. 28.10% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://theolympiareport.com/2017/12/15/acelrx-pharmaceuticals-acrx-receiving-somewhat-positive-news-coverage-report-finds.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.